These findings suggest that ANRIL functions as an epigenetic modifier in NF1, where reduced expression may contribute to increased PNF susceptibility and tumour burden, potentially through modulation of the CDKN2A/B tumour suppressor axis. The gene discussed is CDKN2B-AS1; the disease is neoplasm.